ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Nemolizumab (Nemluvio)

Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

CHMP opinion 12 Dec 2024 → EU licence 12 Feb 2025 · Galderma International

Research

Dermatology · Acta Derm Venereol · 2026-06-10

In 507 adolescents and adults with moderate-to-severe atopic dermatitis responding at week 16, rerandomisation to nemolizumab every 4 or 8 weeks maintained IGA success at week 48 in 61.5% and 60.4% vs 49.7% with withdrawal (placebo); adverse events were similar.

RCTn = 507
Wollenberg et al. Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.